Ipilimumab trials for Lung cancer

All Ipilimumab trials · All Lung cancer trials

Phase breakdown

Recruiting trials studying Ipilimumab for Lung cancer

• A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
  NCT06362369 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab
  NCT04933903 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
  NCT06364917 · Phase: Phase 2 · Ages: 18 Years to 89 Years · Sex: All (male and female) · 1 location
• First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
  NCT07355205 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
  NCT05715229 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
  NCT06047379 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
  NCT05501665 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
  NCT05176483 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 244 locations

Common questions

How many trials study Ipilimumab for Lung cancer?

8 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.